方盛制药（603998）8月25日主力资金净流出6845.33万元

Group 1 - The core viewpoint of the news is that Fangsheng Pharmaceutical (603998) has shown a mixed performance in its latest financial results, with a decrease in total revenue but an increase in net profit [1] - As of August 25, 2025, Fangsheng Pharmaceutical's stock closed at 12.63 yuan, up 3.87%, with a trading volume of 637,500 hands and a transaction amount of 799 million yuan [1] - The company's latest quarterly report indicates total revenue of 418 million yuan, a year-on-year decrease of 4.62%, while net profit attributable to shareholders reached 88.26 million yuan, a year-on-year increase of 25.74% [1] Group 2 - The company has a liquidity ratio of 0.829 and a quick ratio of 0.511, with a debt-to-asset ratio of 44.14% [1] - Fangsheng Pharmaceutical has made investments in 42 companies and participated in 4,804 bidding projects, indicating active engagement in the market [2] - The company holds 115 trademark registrations and 62 patents, along with 169 administrative licenses, showcasing its commitment to intellectual property and regulatory compliance [2]